BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, August 16, 2024
Breaking News: BioWorld celebrates nine wins at 2024 APEX Awards
See today's BioWorld Science
Home
» Onquality Pharmaceuticals China discovers CDK4/6 inhibitors for cancer therapy-associated disorders
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Cancer
Onquality Pharmaceuticals China discovers CDK4/6 inhibitors for cancer therapy-associated disorders
July 12, 2024
No Comments
Onquality Pharmaceuticals China Ltd. has described cyclin-dependent kinase 4 (CDK4) and/or cyclin-dependent kinase 6 (CDK6) inhibitors reported to be useful for the treatment of cancer therapy-associated disorders.
BioWorld Science
Cancer
Patents